csirt@kutim:~/threat-intel/cve/CVE-2026-18432

Katalog CVE

CVSS 9.8 · Critical EPSS 0,84%

Kerentanan Improper Privilege Management. Skor CVSS 3.1 9.8 (Critical) menurut wordfence.com.

Deskripsi (NVD)

The Frontend Admin by DynamiApps plugin for WordPress is vulnerable to Privilege Escalation in all versions up to, and including, 3.29.9. The vulnerability exists because `ActionUser::conditions_logic()` gates the `current_user_can('edit_user', $user_id)` authorization check behind an `is_numeric()` test, causing the check to be skipped entirely when `$user_id` is a non-numeric string — a condition that can be induced by passing a crafted value such as `1one` through the unvalidated `item_id` parameter of the unauthenticated `wp_ajax_nopriv_frontend_admin/forms/change_form` AJAX endpoint. This makes it possible for attackers to escalate privileges to administrator by obtaining a server-signed `_acf_objects` payload carrying the non-numeric user ID, which WordPress subsequently coerces to integer 1 (the default administrator), allowing the attacker to overwrite that account's password or email address. Exploitation by unauthenticated users requires a public-facing frontend user form to be configured; in all other cases a subscriber-level account is sufficient.

Rincian

Terbit di NVD
16 Agustus 2026
Terakhir diubah
20 Agustus 2026
Status NVD
Deferred
CVSS 3.1
9.8 (Critical), sumber wordfence.com
CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:H/I:H/A:H · uraikan di kalkulator
Jenis kelemahan (CWE)
CWE-269: Improper Privilege Management
EPSS (30 hari)
0,84% peluang dieksploitasi; lebih tinggi dari 56,6% CVE lain

Produk dan versi terdampak

NVD belum mencantumkan data produk (CPE) untuk CVE ini. Produk yang terdampak biasanya disebut di deskripsi dan di advisory vendor pada daftar referensi.

Referensi dan perbaikan

Sumber: NVD · CVE.org · EPSS. Halaman ini disusun otomatis dari data tersebut; pembaruan terakhir 5 Okt 2026, 20:11 WITA. Kalau sistem di Perangkat Daerah memakai produk ini dan butuh bantuan, laporkan lewat kanal pelaporan.